Blood(µg/ml)

Liver (µg/gm tissue)

  Kideny(µg/gm tissue)

Brain(µg/gm tissue)

 

Zinc

Fe

Zinc

Fe

Zinc

Fe

Zinc

Fe

Control group

4.11 ±  0.28

2.89 ±  0.21

38.96 ±  2.45

15.65 ±  1.02

20.11 ±  1.25

9.61 ±  1.58

10.25 ±  0.98

20.12

Cd exposed group

6.37 ±  0.55***

0.33 ±  0.014***

21.04 ±  3.22***

8.87 ±  1.56***

18.96 ±  1.93ns

3.67 ±  0.59***

6.69 ±  0.71***

6.78 ±  1.15***

Ceftriaxone plus sulbactam with VRP1034 group

5.02 ±   0.19***

0.72 ±  0.011***

24.56 ±  1.5*

10.23 ±  2.10ns

19.44  ±  2.78ns

5.03 ±   0.97*

9.85 ±  1.28***

13.87 ±  2.31***
All data are Mean ± SD of each group. Newman keuls test was performed for statistical significance between control group vs Cd exposed group and Cd exposed group vs ceftriaxone plus sulbactam with VRP1034 treated group. Where ***p<0.001(highly significant) **p<0.01(significant); *p<0.05(significant); Nsp>0.05(non significant).
Table 8: Effect of ceftriaxone plus sulbactam with VRP1034 on Zinc and Fe levels in blood and tissues after 20 days treatment.